Articles for category: Most Popular

The whipping post

Notable Monday Option Activity: MSFT, NVDA, AAPL

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Microsoft Corporation (Symbol: MSFT), where a total of 268,007 contracts have traded so far, representing approximately 26.8 million underlying shares. That amounts to about 123.1% of MSFT’s average daily trading volume over the past month of 21.8 million ...

The whipping post

How a Floor Trader Turned Wall Street’s Chaos Into a System

Editor’s Note: Eric Fry, here. Every once in a while, a story comes along that reminds us how the best market strategies aren’t born in boardrooms… they’re forged in the chaos of real trading floors. My colleague Jonathan Rose spent decades on the floors of Chicago’s biggest exchanges, learning to read the market’s rhythm in ...

The whipping post

3 Incredible Growth Stocks to Buy Right Now With $300

Key Points Growth stocks have been outperforming for the last 15 years. These three stocks have strong positions in cloud computing and enterprise software. Their valuations are all relatively attractive, and you can buy shares for less than $300. 10 stocks we like better than Alibaba Group › Growth stocks aren’t just having a moment; ...

The whipping post

1 Bold Prediction for Tesla in 2026

Key Points Tesla (NASDAQ: TSLA) CEO Elon Musk is going all in on robotaxis. He predicts “millions” of Tesla robotaxis to be on the streets of America in 2026. Much of Tesla’s valuation is likely tied up in its robotaxi ambitions. But investors should be hesitant about Musk’s predictions given the data below. Waymo’s growth ...

The whipping post

Cadrenal Therapeutics, Inc.

Valuation Based on our probability adjusted DCF model that takes into account potential future revenues for tecarfarin in LVADs, ESKD+AFib, and mechanical heart valves, CVKD is valued at $30.00/share. This model is highly dependent upon continued clinical success of tecarfarin and will be adjusted accordingly based upon future clinical results.  Highlight Based on our probability ...